Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Odanacatib, developed by Merck & Co., is one of the most extensively studied cathepsin K inhibitors. It has demonstrated high potency and selectivity for cathepsin K, with promising results in increasing bone mineral density in postmenopausal women with osteoporosis. However, the development of odanacatib was terminated due to concerns over cardio-cerebrovascular adverse effects